Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer
Active analgesic use with aspirin or non-aspirin NSAIDs within 2 years after diagnosis may improve the survival outcomes of patients with ovarian cancer, according to a study published in The Lancet Oncology.1
Outcomes among patients with ovarian cancer have not substantially improved despite the advancements in therapy. Increasing evidence has demonstrated that inflammation may negatively affect prognosis, and previous studies have suggested that analgesic medicine use may have a protective effect for this patient population.
Researchers assessed data from 2 longitudinal cohort studies. Participants in the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII) — ongoing long-term prospective studies that contain 121,700 and 116,429 US nurses, respectively — completed biennial questionnaires detailing analgesic use (eg, aspirin, ibuprofen, naproxen, paracetamol). By linking the data to the Surveillance, Epidemiology, and End Results (SEER) cancer registry, investigators were able to identify patients who were diagnosed with ovarian cancer.
Read more from Cancer Therapy Advisor, by James Them on Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer
Shane Maritch/Shutterstock.com
